L. Becquemont, Pharmacogenomics of adverse drug reactions: practical applications and perspectives, Pharmacogenomics, vol.64, issue.6, pp.961-970, 2009.
DOI : 10.1067/mcp.2000.104944

K. Crews, J. Hicks, C. Pui, and M. Relling, Pharmacogenomics and Individualized Medicine: Translating Science Into Practice, Clinical Pharmacology & Therapeutics, vol.154, issue.4, pp.467-75, 2012.
DOI : 10.1056/NEJMra020526

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589526/pdf

W. Evans and H. Mcleod, Pharmacogenomics ??? Drug Disposition, Drug Targets, and Side Effects, New England Journal of Medicine, vol.348, issue.6, pp.538-587, 2003.
DOI : 10.1056/NEJMra020526

J. Vand-er-weide and L. Steijns, Cytochrome P450 Enzyme System: Genetic Polymorphisms and Impact on Clinical Pharmacology, Annals of Clinical Biochemistry: An international journal of biochemistry and laboratory medicine, vol.36, issue.6, pp.722-751, 1999.
DOI : 10.1177/000456329903600604

D. Nebert, Clinical importance of the cytochromes P450, The Lancet, vol.360, issue.9340, pp.1155-62, 2002.
DOI : 10.1016/S0140-6736(02)11203-7

M. Ingelman-sundberg, Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future, Trends in Pharmacological Sciences, vol.25, issue.4, pp.193-200, 2004.
DOI : 10.1016/j.tips.2004.02.007

G. Tucker, Advances in Understanding Drug Metabolism and Its Contribution to Variability in Patient Response, Therapeutic Drug Monitoring, vol.22, issue.1, pp.110-113, 2000.
DOI : 10.1097/00007691-200002000-00023

H. Loovers and J. Er-weide, Implementation of CYP2D6 genotyping in psychiatry, Expert Opinion on Drug Metabolism & Toxicology, vol.27, issue.9, pp.1065-77, 2009.
DOI : 10.1097/GIM.0b013e31815bf9a3

G. Alvan, L. Bertilsson, M. Ingelman-sundberg, and F. Sjöqvist, Moving toward genetic profiling in patient care: the scope and rationale of pharmacogenetic/ecogenetic investigation, Drug Metab Dispos Pt2, vol.29, issue.4, pp.580-585, 2001.

M. Vincent-viry, J. Muller, B. Fournier, M. Galteau, S. et al., Relation between debrisoquine oxidation phenotype and morphological, biological, and pathological variables in al arge population, Clin Chem, vol.37, pp.327-359, 1991.

N. Diaz, Laboratory Testing for HER2/neu in Breast Carcinoma: An Evolving Strategy to Predict Response to Targeted Therapy, Cancer Control, vol.19, issue.12, pp.415-423, 2001.
DOI : 10.1200/JCO.2001.19.10.2587

S. Lee, P harmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application, JP athol, vol.223, issue.1, pp.15-27, 2011.

M. Pirmohamed, G. Burnside, N. Eriksson, A. Jorgensen, H. To-hc et al., Ar andomized trial of genotypeguided dosing of warfarin, NE ngl JM ed, vol.369, issue.24, pp.2294-2303, 2013.

T. Verhoef, G. Ragia, A. De-boer, R. Barallon, . Kolovoug et al., Ar andomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon, NE ngl JM ed, vol.369, issue.24, pp.2304-2316, 2013.

M. Holmes, P. Shah, T. Hingorani, and A. , CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events, JAMA, vol.306, issue.24, pp.2704-2718, 2011.
DOI : 10.1001/jama.2011.1880

URL : http://jama.jamanetwork.com/data/journals/jama/22480/jcr15007_2704_2714.pdf

J. Swen, T. , H. De-vries, E. , W. et al., Translating Pharmacogenomics: Challenges on the Road to the Clinic, PLoS Medicine, vol.12, issue.8, pp.1317-1341, 2007.
DOI : 10.1371/journal.pmed.0040209.t004

S. Mallal, E. Phillips, G. Carosi, J. Molina, C. Workman et al., HLA-B*5701 Screening for Hypersensitivity to Abacavir, New England Journal of Medicine, vol.358, issue.6, pp.568-79, 2008.
DOI : 10.1056/NEJMoa0706135

A. Foster, Z. Wang, M. Usman, E. Stirewalt, and P. Buckley, Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians, Neuropsychiatric Disease and Treatment, vol.3, issue.6, pp.965-73, 2007.
DOI : 10.2147/NDT.S1752

J. Ciccolini, E. Gross, B. Dahanl, and C. Mercier, Routine Dihydropyrimidine Dehydrogenase Testing for Anticipating 5-Fluorouracil???Related Severe Toxicities: Hype or Hope?, Clinical Colorectal Cancer, vol.9, issue.4, 2010.
DOI : 10.3816/CCC.2010.n.033

M. Ratain, CYP2D6 Genotype and Tamoxifen Activity: Understanding Interstudy Variability in Methodological Quality, Clinical Pharmacology & Therapeutics, vol.3, issue.2, pp.185-192, 2013.
DOI : 10.1186/gm280

M. Kurzawski and M. Drozdzik, Pharmacogenetics in solid organ transplantation: genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugs, Pharmacogenomics, vol.14, issue.9, pp.1099-1117, 2013.
DOI : 10.1016/j.trim.2004.11.001

E. Thervet, M. Loriot, S. Barbier, M. Buchler, M. Ficheux et al., Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing, Clinical Pharmacology & Therapeutics, vol.87, issue.6, pp.721-747, 2010.
DOI : 10.1097/00007890-200212150-00002

D. Ge, . Fellayj, A. Hompson, J. , K. Rban et al., Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance, Nature, vol.18, issue.7262, pp.399-401, 2009.
DOI : 10.1038/nature08309

L. Cardon, R. Idury, T. Harris, J. Witte, and R. Elston, Testing drug response in the presence of genetic information: sampling issues for clinical trials, Pharmacogenetics, vol.10, issue.6, pp.503-513, 2000.
DOI : 10.1097/00008571-200008000-00003

V. Huser and J. Cimino, P roviding pharmacogenomics clinical decision support using whole genome sequencing data as input, AMIA Jt Summits Transl Sci Proc, vol.2013, pp.81-3814493, 2013.